Proteonomix, Inc. (PROT) 股价，以美元计价

Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies Regenerative therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. We are primarily focused on developing therapies and products based upon the use of human stem cells and their derivatives with an initial focus on diabetes and cardiac diseases. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include but are not limited to cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy, often referred to as "Regenerative Medicine" or "Cellular Medicine," provides much promise for the treatment of diseases previously regarded as incurable. Through our operating subsidiary, National Stem Cell, Inc. ("National Stem Cell"), we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in: a. the development of identification biomarkers, cell derivatives and cellular proteins. b. the development of stem cell therapies for disease and injury; and c. the performance of reproductive cell/tissue laboratory services. In addition to our work with stem cell therapeutics, we intend to develop a myriad of derivative commercial products using stem cells. Our wholly-owned subsidiary, Proteoderm, Inc. ("Proteoderm") has designed and intends to produce and market, anti-aging cosmeceuticals and cosmetics derived from stem cell products which contain a patent pending secreted matrix as an active ingredient.